Disclosure Devil - Summary

ASX ANNOUNCEMENT 13 NOVEMBER 2025 75% disease control observed in CHM CDH17 Phase 1/2 Clinical Trial • Six of 8 (75%) evaluable subjects with disease control at 28 days • Five of 6 (83%) with ongoing stable disease including 1 patient approaching 1 year without additional anticancer therapy • Four of 4 (100%) of subjects treated at dose level 2 with ongoing stable disease Sydney, Australia, 13 November 2025: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to announce it has achieved continued disease control and tumour shrinkage in its CHM CDH17 Phase 1/2 clinical trial. Four study subjects have been treated at Dose Level 2, with all achieving stable disease per the RECIST 1.1 Criteria as part of their tumour assessments. Currently 75% of the 8 evaluable subjects treated in the trial have achieved disease control at 28 days RECIST 1.1 is measured by changes in tumour size seen on scans. A Complete Response (CR) means all visible tumours have disappeared. A Partial Response (PR) means the total tumour size has shrunk by at least 30%. Stable Disease (SD) means the cancer has shrunk up to 30% or has not grown more than 20% from nadir. Progressive Disease (PD) indicates tumour growth of 20% or more, or the appearance of new tumours.¹ In addition to the positive results emerging from Dose Level 2, one ColoRectal Cancer (CRC) patient from the Dose Level 1 cohort continues to demonstrate stable disease, per RECIST, more than 11 months after receiving a single dose of CHM CDH17. This patient has not had any other treatments throughout this time. “It is encouraging to see this progress for CHM CDH17 and the impact on patients is remarkable” said Chimeric Therapeutics CEO Dr Rebecca McQualter. “We look forward to reporting further updates including greater detail around the duration of these responses.” The Phase 1/2 trial (NCT06055439) is a two-stage study designed to determine a recommended Phase 2 dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and gastrointestinal NETs. CHM CDH17 is a 3rd generation, novel CAR-T cell therapy that targets CDH17, a cancer biomarker associated with poor prognosis and metastases in the most common gastrointestinal tumours. The Phase 1 portion of this study is expected to enrol up to 15 patients and lead to dose selection and expansion with indication-specific Phase 2 cohorts. ¹ https://dctd.cancer.gov/research/ctep-trials/for-sites/recist-guidelines-v11.pdf For personal use only ABOUT CHIMERIC THERAPEUTICS Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. Chimeric’s world class team of cell therapy pioneers is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies. Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs. CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR T was published by Dr. Hua and his colleagues in March 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024. CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets. CHM CLTX is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CLTX CAR T is a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023. Authorised on behalf of the Chimeric Therapeutics board of directors by Executive Chairman Paul Hopper Contact Investors Dr Rebecca McQualter Chief Executive Officer Chimeric Therapeutics E: investors@chimerictherapeutics.com W: www.chimerictherapeutics.com Media Matthew Wright NWR Communications T: +61 451 896 420 E: matt@nwrcommunications.com.au For personal use only